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Implantation of Continuous-Flow
Ventricular Assist Devices: Technical Considerations
Ranjit John, MDThe increased applicability and excellent results with leftventricular assist devices (LVADs) have revolutionized
the treatment options available for patients with end-stage
heart failure. Until recently, pulsatile devices have supported
most patients who have undergone LVAD implantation. Al-
though tremendous success has been achieved with these
devices, their use is associated with significant comorbidity.
This may be related to several factors including the need for
extensive surgical dissection, a large pump, and a large-di-
ameter percutaneous lead. Even more importantly, their
long-term durability is limited and frequently requires reop-
eration for device exchange, that often result in significant
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progress has been made with the use of the newer LVADs
such as HeartMate II (HM II, Thoratec, Pleasanton, CA),
which incorporate continuous-flow, rotary pump technol-
ogy, representing the next generation of devices that are ad-
vancing the field.1 Continuous-flow rotary pumps have dem-
onstrated enhanced durability and provide improved quality
of life for extended periods of support. A major advantage of
these new pumps is their small size, thereby extending ther-
apy to underserved patient populations including women
and children. In the current era, continuous-flow devices
have rapidly become the standard of care for virtually all
patients with heart failure, with excellent outcomes being
reported thus far.
Although the majority of the surgical techniques discussed
in this article pertain to the HM II LVAD (currently the most
commonly used continuous-flow device), the surgical prin-
ciples and techniques discussed here can be used as a tem-
plate for the implantation of any other currently used contin-
uous-flow LVAD.2
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144 R. JohnOperative Technique
Figure 1 Surgical setup. An overall
setup similar for other open-heart
operations is usually adequate. Periop-
erativemedications include the admin-
istration of antibiotics (usually broad-
spectrum antibiotics with antifungal
coverage). A Foley urine catheter and a
Swan–Ganz catheter are placed if pa-
tients do not have one. Although all
potential LVAD patients would nor-
mally have had a right heart catheter-
ization during their initial evaluation,
the need to determine their CVP and
PA pressures following intubation
might influence the necessity for addi-
tional peri- and postoperative pulmo-
nary vasodilator therapy such as nitric
oxide, depending on the predicted
right heart failure risk. Transesopha-
geal echocardiogram is performed to
detect the presence of a patent foramen
ovale (PFO) as well as to evaluate the
presence of moderate or greater aortic
incompetence (either of which will al-
ter usual surgical techniques). A stan-
dardmedian sternotomy is performed.
Preparation for cardiopulmonary by-
pass (CPB) includes activated coagula-
tion time (ACT)-guided heparinization
and the administration of Amicar. Aor-
tic cannulation and right atrial cannu-
lation are performed in a standard fash-
ion. Bicaval cannulation is only
performed if a PFO is detected or tri-
cuspid valve repair or replacement is
considered. In patients with a prior
sternotomy, external defibrillator pads
are placed and the groin is prepped for
possible rapid access to the femoral
vessels in case of injury to the heart
during sternal reentry.
CPB timemay be minimized by cre-
ating the LVAD pump pocket, sewing
of outflow graft, and exiting driveline
prior to institution of CPB. However,
for reasons mentioned later in this arti-
cle, my personal preference is to per-
form all these portions of the operation
after CPB is instituted. IVC  inferior
vena cava; PA  pulmonary artery;
SVC superior vena cava.
Implantation of continuous-flow ventricular assist devices 145Figure 2 Creation of LVAD pump pocket. Creation of an adequately sized pump pocket is essential to optimize inflow
cannula position. For the HM II LVAD, the exposed part of the diaphragm is cauterized as far as possible laterally. In
addition, dividing the pericardial reflection laterally beyond the left ventricular (LV) apex is also necessary (this
maneuver alone is sufficient for the HeartWare LVAD, which is placed in an intrapericardial position). A significant
number of patients undergoing LVAD placement may have an LV apical clot; creation of the pump pocket requires
manipulation of the LV apex and increases the risk for potential LV clot dislodgment. This is our rationale for creating
the pump pocket following the institution of CPB. This increases the risk of bleeding because of heparinization; hence,
meticulous hemostasis should be done after completion of the pump pocket as this area is not easily visualized once the
LVAD pump is placed.
146 R. JohnFigure 3 Placement of LVAD inflow cannula. Although there are specific tools available for each of the currently used
continuous-flow LVADs, certain common principles are essential. During CPB, either a circular coring device or an 11
blade is used for creating the LV apical core (A, B, and C). A 2-0 Tevdek (Johnson & Johnson, Somerville, NJ) suture
placed at this location and brought through the coring knife facilitates traction on the apical portion being cored (C).
t
t
p
i
e
m
t
t
t
t
a
t
p
t
p
a
f
b
(
b
l
2
f
m
t
r
Implantation of continuous-flow ventricular assist devices 147Figure 3 (Continued) The ideal posi-
ion is usually 1-2 cm anterolateral to
he apical dimple, which is an easily
alpable location. The location of the
nflow cannula is critical for both
arly- and long-term pump perfor-
ance. By choosing the correct posi-
ion on the LV apex, the ideal orien-
ation of the inflow cannula pointing
oward the mitral valve and parallel
o the ventricular septum can be
chieved (creating adequate space for
he pump pocket is also important to
revent inadvertent malposition of
he inflow cannula). A full-thickness
iece of myocardial core is removed
nd the opening is inspected closely
or thrombi or adjacent trabeculae,
oth of which are carefully removed
chronic thrombus, that is well em-
edded and adherent to the ventricu-
ar wall, can be left alone; D). Next,
-0 Tevdek sutures are placed in a
ull-thickness fashion through the
yocardial core and passed through
he felt portion of the sewing cuff or
ing (E).
148 R. JohnFigure 3 (Continued) These sutures are either pledgetted or one can use a large circular Teflon donut piece as shown (F).
These sutures are then tied down carefully to secure the sewing cuff or ring to the apical opening. The inflow cannula
is then inserted through this opening and secured adequately (G). In the case of the HM II LVAD, additional reinforce-
ment with a tie band or umbilical tape is used. In the case of the HeartWare LVAD, the inflow cannula is secured by
tightening an integrated screw in the titanium sewing ring.
Implantation of continuous-flow ventricular assist devices 149Figure 4 Tunneling of the driveline. Asmentioned earlier, the driveline exitwound can be performedprior to institution ofCPB to
minimizebleedingat thedriveline track.However,mypreference is todotheLVADpumpplacementfirstandthendecide theexact
track of the driveline wound. All currently available drivelines have been coated with a polyester velour covering that allows for
subcutaneous tissue ingrowth. Currently, my preference is to leave the end of the polyester-covered portion of the driveline
completelywithin the subcutaneouswound (leaving the junction of the polyester and smoothportion at least 1-2 cm from the exit
site). The actual exit site is typically about 4fingerbreadths below the right costalmargin in themidclavicular line. Technical factors
that will reduce the risk of driveline infections includemaking the driveline tunnel as long as possible within the abdomen aswell
asmaneuvers to stabilize thedriveline even in the immediatepostoperativeperiod. I typicallyplace a skin suture at thedriveline exit
wound site that is removed 4-6 weeks postoperatively when the wound is well healed.
150 R. JohnFigure 5 Outflow graft placement. The outflow graft is anastomosed to the anterolateral portion of the midascending aorta.
Although this portion canbedoneprior to institution ofCPB, determining the exact length of the outflowgraft is ideally done after
positioning the LVADpump (A). Avoidance of excess graft length is important to avoid kinking of the outflowgraft. Grafts that are
too short may cause tension on the anastomosis, leading to anastomotic site bleeding or even the possibility of increased afterload
resistance at the outflow graft anastomotic site; in addition, grafts that are short may cause them to lie closer to the midline, thus
increasing the risk of graft injury during sternal reentry.Once the length of the graft is determined, a partial aortic occlusion clamp
isplacedand the anastomosisperformedwith a4-0polypropylene suture (B). Typically, pledgets arenotused for this anastomosis.
Once completed, hemostasis can be ascertained by removal of the partial occluding clamp. Always place a vascular clamp on the
outflow graft with a continuous flow LVAD to avoid backflow into the left ventricle (C).
As a heart transplant operation in patients with LVADs is more complex, strategies instituted at the time of LVAD
placementmight facilitate safer LVAD explant as well as conduct of the entire operation at the time of heart transplantation.3
The LVAD outflow graft should be directed toward the right atrial gutter so as to avoid injuring it during sternal reentry.
Further, the outflow graft anastomosis should be placed on the lateral aspect of the aorta as proximal as possible so as to leave
adequate room for both aortic cannulation as well as the aortic anastomosis during the subsequent transplant. The plane
between the aorta and the pulmonary artery is also preferably left undisturbed to allow easier dissection around the aorta at
the time of subsequent transplant. It is ideal to avoid the use of Teflon pledgets at cannulation sites at the time of LVAD
placement as this might reduce the degree of scarring and facilitate easier aortic dissection at the time of transplant.
Implantation of continuous-flow ventricular assist devices 151Figure 6 Deairing maneuvers and weaning off CPB. The outflow graft is connected to the pump. It is important to place
a cross-clamp on the outflow graft with continuous-flow devices until LVAD output is initiated to prevent backflow of
blood into the left ventricle. Typically, deairing maneuvers include placing the patient in a Trendelenburg position,
adding volume to the heart, and resuming ventilation. A large-bore needle is also placed in the outflow graft. In
addition, a vent can be placed in the ascending aorta (A). Deairing is confirmed by transesophageal echocardiogram (B).
A combination of inotropic and vasopressor support is usually started. Following this, the patient is gradually weaned
to 1 L/min CPB flow and the LVAD pump is started. The speed of the pump is gradually increased to allow for
increased LVAD output and CPB is discontinued. Transitioning from CPB to LVAD support must involve close
communication between the surgeon, anesthesiologist, perfusionist, and LVAD operating team. Optimization of
inotropic and vasopressor support is continued based on hemodynamic parameters. Close attention is paid to the
transesophageal echocardiogram to monitor the presence of air, inflow cannula position, right ventricular (RV) func-
tion, septal wall motion, LV decompression as well as mitral, tricuspid, and aortic valve competence. A bubble test is
performed to rule out a PFO. After ensuring hemodynamic stability, protamine is administered and all cannulas are
removed. Close attention is paid to achieving meticulous hemostasis. Standard chest tubes are used typically with a
large Blake drain used in the vicinity of the LVAD pump pocket. Despite careful measures to obtain hemostasis, it is
sometimes necessary to leave the chest open and return in 24-48 hours for subsequent chest closure.
The use of various protective barriers to prevent injury to the right ventricle during resternotomy such as Gor-Tex
mesh (W.L. Gore Co., Newark, DE) or CorMatrix (CorMatrix Cardiovascular Inc, Alpharetta, GA) is increasingly being
used. Although unclear at this point in time, the use of some protective barriers might favorably influence the degree
of scarring and adhesion formation and thereby facilitate easier dissection of the heart and LVAD for explant.
152 R. JohnFigure 7 Dealing with moderate or greater aortic incompetence. If moderate or greater aortic incompetence is detected (ideally
before thepatient isbrought to theoperating room), then the surgical technique isusually altered.4Althoughvarious strategieshave
been reported to treat aortic incompetence at the time of LVAD implantation, themost commonly used technique involves aortic
valve closure either with a singlemulti-pledgetted 4-0 prolene suture or with the use of a felt strip along each leaflet. Replacement
of the aortic valve with a bioprosthetic valve is also used; however, the longer ischemic time needed as the well as reports of early
fusionof the leaflets of thebioprosthetic valvehas reduced thepopularity of this approach.Anaggressive approach to the treatment
of moderate aortic incompetence is paramount as the worsening of aortic incompetence that has been reported following contin-
uous-flow LVAD implantation will eventually result in refractory heart failure.
Correction of aortic incompetence during LVAD implantation requires the placement of a cross-clamp and the adminis-
tration of cardioplegia via the retrograde route or directly into the coronary ostia. My preference is to perform an aortotomy
at the site where usually an aortotomy is performed for routine aortic valve replacement. Attempting to repair the aortic valve
through the site of the aortotomy intended for outflow graft anastomosis is technically challenging as this site is more distal
on the aorta. Following repair of the aortic valve, the aortotomy is closed, the cross-clamp is released, and the rest of the
operation including the inflow cannula and the outflow graft placement is conducted in the usual fashion.
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Implantation of continuous-flow ventricular assist devices 153LVAD Pump Exchange
Although the LVAD pump exchange is infrequently done, it
is usually done with a left subcostal approach that gives direct
access to the pump and the inflow cannula.5 CPB is essential
and can be easily performed with femoral arterial and venous
cannulation. Most commonly, only the inflow cannula and
the LVAD pump need to be changed and the existing outflow
graft can be preserved and connected to the new pump. The
driveline is usually tunneled to a different position, on either
upper quadrant of the abdomen.
Temporary RV Failure
Proper patient selection and optimization of hemodynamics
have significantly minimized the risk of RV failure at the time
of LVAD placement.6 However, the occurrence of RV failure
esulting in hemodynamic compromise should be treated
ggressively by medical measures including optimizing ino-
ropic and vasopressor therapy as well as aggressive pulmo-
ary vasodilator therapy such as nitric oxide. If such mea-
ures do not ameliorate RV failure, then placement of a
emporary right ventricular assist device such as a Centrimag
Thoratec Corp., Pleasanton, CA) or a Biomedicus device
Medtronic, Minneapolis, MN) is indicated.
Conclusions
In conclusion, there is an increased usage of continuous-
flow LVADs for the treatment of end-stage heart failure.
Newer continuous-flow pumps have resulted in superior
outcomes, including significantly reduced complication
rates with improved durability over first-generation pul-
satile design pumps. However, as with all new technology,
the newer LVADs have introduced management chal-
lenges that were either unimportant or absent with pulsa-
tile LVADs. Despite these concerns, an overall improve-ment in outcomes has been clearly demonstrated with the
newer continuous-flow devices, as compared with pulsa-
tile devices. These improvements are due primarily to the
many advantages of the newer devices and secondarily to
lessons learned from the earlier experiences with pulsatile
devices, including more careful patient selection, better
preoperative optimization, improved operative tech-
niques, and enhanced postoperative management (eg, op-
timization of RV function). In conclusion, LVADs have
revolutionized the manner in which advanced heart failure
is treated. Substantial strides have been made from the
initial versions of mechanical support to the devices that
are used today. With an aging population, limited donor
heart availability, improved reliability of mechanical car-
diac support, and improved patient outcomes, LVAD op-
tions to support end-stage heart failure patients are rapidly
expanding.
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